Iovance Biotherapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.

CEO

Frederick G. Vogt

CEOFrederick G. Vogt

Employees

319

Employees319

Headquarters

San Carlos, California

HeadquartersSan Carlos, California

Founded

2007

Founded2007

Employees

319

Employees319

IOVA Key Statistics

Market cap

1.29B

Market cap1.29B

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

7.03M

Average volume7.03M

High today

$8.43

High today$8.43

Low today

$7.92

Low today$7.92

Open price

$8.24

Open price$8.24

Volume

7.54M

Volume7.54M

52 Week high

$18.73

52 Week high$18.73

52 Week low

$5.42

52 Week low$5.42

IOVA News

Yahoo Finance 5d

Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M - Yahoo Finance

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has agreed to acquire worldwide rights to Proleukin (aldesleukin), an interleukin-2 (IL-2) product, from Clinigen Lim...

Yahoo Finance 5d

Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates - Yahoo Finance

Iovance Biotherapeutics, Inc. Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Fut...

Analyst ratings

73%

of 15 ratings

Buy

73.3%

Hold

26.7%

Sell

IOVA Earnings

-$0.64

-$0.43

-$0.21

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Feb 23, After Hours

ActualExpected Feb 23, After Hours